Skip to main content
letter
. 2016 Dec 5;24(11):1889–1891. doi: 10.1038/mt.2016.192

Figure 2.

Figure 2

Effects of targeting the Mstn gene in skeletal muscle cells in mice with cancer-associated muscle atrophy. (a) Tumor volume (direct measurement) and fat mass (analyzed by NMR) in live animals each week after tumor cell engraftment. (b) Tumor-free body weight at week 0 (starting body weight) and week 8 (body weight at the end point with tumor weight subtracted) in mice treated with AAV-SaCRISPR-Mstn or AAV-GFP-2a-Luci viruses. (c) Serum concentration of myostatin measured by ELISA in animals from indicated groups at week 8. (d) Gastrocnemius and soleus muscle weight in animals from indicated groups measured at week 8. (e) Grip strength of limbs measured in live animals from indicated groups at week 8. (f) Hematoxylin-eosin stains of cross-sectional areas of gastrocnemius muscles of representative mice from indicated groups at week 8. Scale bar = 200 µm. In a–e, n = 6 mice for AAV-SaCRISPR-Mstn or AAV-GFP-2a-Luci group; n = 10 for tumor-free control group. Error bars show standard error of the mean. The unpaired, two-tailed Student's t-test was used for statistical analysis in a and b. One-way analysis of variance, post-hoc Bonferroni multiple-comparison test was used for statistical analysis in c–e. *P < 0.05; **P < 0.01. AAV, adeno-associated virus; ELISA, enzyme-linked immunosorbent assay; n.s., not significant.